E-DRUG: Open Forum 3 - Key Issues in TB Drug Development, May 5-6 in New Delhi
-------------------------------------------------------------------------
Meeting Announcement: Open Forum 3 - Key Issues in TB Drug Development,
May 5-6th 2008 in New Delhi, India
This two-day Open Forum is the third in a series of meetings aimed to
raise and address key issues in TB drug development, with a special
focus on regulatory affairs. The Forum will include sessions on the
current global TB drug development portfolio, key issues in the critical
path to TB drug registration, designing pivotal trials, conducting
registration trials in high burden countries, challenges in TB drug
development for resistant disease and developing regimens containing
multiple novel agents. These meetings are designed to bring together
regulators, TB drug developers and other interested stakeholders, such
as TB care providers, public health policy-makers, and community
advocates from both major industrialized and high burden countries.
The meeting is being organized and sponsored by Global Alliance for TB
Drug Development (TB Alliance), the Bill & Melinda Gates Foundation, The
Stop TB Partnership Working Group on New Drugs, and Treatment Action
Group.
The meeting is supported in part by unrestricted educational grants from
AstraZeneca, Bayer, GlaxoSmithKline and Johnson & Johnson/Tibotec.
Pre-registration is required and registration is free.
For more information about this event, and to register, please go to:
http://www.tballiance.org/events/openforum3.php
For inquiries, please contact the Conference Secretariat, at
rsvp@tballiance.org
Anna Upton
TB Alliance
e-mail: <anna.upton@tballiance.org>